Acute Myeloid Leukemia Market Report 2026

The acute myeloid leukemia market size has grown strongly in recent years. It will grow from $3.73 billion in 2025 to $3.97 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising prevalence of aml, growing hospital infrastructure, increasing awareness about leukemia treatments, adoption of conventional chemotherapy protocols, development of supportive care measures.

The acute myeloid leukemia market size is expected to see strong growth in the next few years. It will grow to $5.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to advancement in targeted therapy drugs, increasing stem cell transplant procedures, development of novel tyrosine kinase inhibitors, expansion of ambulatory care centers, integration of personalized medicine approaches in treatment. Major trends in the forecast period include increasing adoption of targeted aml therapies, rising use of stem cell transplantation procedures, growing demand for personalized chemotherapy regimens, expansion of tyrosine kinase inhibitors and monoclonal antibodies, enhanced focus on early diagnosis and aml monitoring.

The increasing adoption of personalized medicine is expected to drive the growth of the acute myeloid leukemia market going forward. Personalized medicine is an innovative healthcare approach that considers individual differences in patients’ genes, environments, and lifestyles. In acute myeloid leukemia (AML), personalized medicine is applied through molecular profiling to identify specific genetic mutations and biomarkers unique to each patient. This information guides the selection of targeted therapies and tailored treatment plans, optimizing treatment effectiveness while minimizing side effects, resulting in a more precise approach to AML management. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based healthcare organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the growing adoption of personalized medicine is fueling the growth of the acute myeloid leukemia market.

Major companies operating in the acute myeloid leukemia market are focusing on developing advanced drug solutions, such as maintenance monotherapy, to expand their portfolios, improve patient outcomes, and address unmet medical needs. Maintenance monotherapy is a treatment approach in which a single therapeutic agent is administered as an ongoing, long-term therapy to prevent recurrence or progression of a disease. For instance, in July 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, received US FDA approval for quizartinib (Vanflyta) in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy for adults with newly diagnosed acute myeloid leukemia (AML) with FLT3 internal tandem duplication (ITD)-positive status, as determined by an FDA-approved test. The LeukoStrat CDx FLT3 Mutation Assay was also approved as a companion diagnostic for Vanflyta. The approval was based on positive results from the QuANTUM-First trial, which showed a statistically significant improvement in overall survival for patients receiving quizartinib versus placebo. Quizartinib’s recommended dosage varies across induction, consolidation, and maintenance phases and is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

In March 2023, QIAGEN, a Netherlands-based biotechnology company, partnered with Servier Laboratories for an undisclosed amount. The partnership aims to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor for treating acute myeloid leukemia (AML). Under the Master Collaboration Agreement, QIAGEN will develop and validate a real-time PCR test to detect IDH1 gene mutations in AML patients using blood and bone marrow samples. This collaboration improves global accessibility of TIBSOVO for AML patients with IDH1 mutations and reinforces QIAGEN’s role in developing companion diagnostics for emerging onco-hematology biomarkers, furthering precision medicine initiatives. Servier Laboratories is a France-based pharmaceutical company.

Major companies operating in the acute myeloid leukemia market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Servier Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Agios Pharmaceuticals Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Genmab AS, Aptose Biosciences Inc., Daiichi Sankyo Company Limited, BeiGene Ltd., Jazz Pharmaceuticals plc, Ipsen S.A.

North America was the largest region in the acute myeloid leukemia market in 2025. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the acute myeloid leukemia market by increasing the cost of imported chemotherapy drugs, stem cell transplantation equipment, and targeted therapy agents. Segments such as tyrosine kinase inhibitors, monoclonal antibodies, and stem cell transplants are most impacted, with north america, europe, and asia-pacific regions facing higher import costs. These tariffs have caused increased treatment expenses and supply chain delays. On the positive side, they have encouraged local drug manufacturing, investment in domestic healthcare infrastructure, and innovation in treatment delivery methods.

The acute myeloid leukemia market research report is one of a series of new reports that provides acute myeloid leukemia market statistics, including acute myeloid leukemia industry global market size, regional shares, competitors with a acute myeloid leukemia market share, detailed acute myeloid leukemia market segments, market trends and opportunities, and any further data you may need to thrive in the acute myeloid leukemia industry. This acute myeloid leukemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute myeloid leukemia (AML) is a type of blood cancer caused by abnormal white blood cells in the bone marrow. The hallmark of AML is the excessive production of immature white blood cells, called myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from producing healthy blood cells.

The main treatment types for acute myeloid leukemia include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapy. Chemotherapy is a drug-based treatment that uses potent chemicals to destroy fast-growing cells in the body. AML chemotherapy includes drugs such as cytarabine, anthracyclines, alkylating agents, antimetabolites, tyrosine kinase inhibitors, and hormonal therapies, administered in various regimens including DC, AVD, and VCD. AML treatments are provided by end users such as hospitals, retail pharmacies, ambulatory care centers, and clinics.

The acute myeloid leukemia market includes revenue earned by drugs such as DC regimen, AVD Regimen, VCD regimen, cytarabine, vidaza, dacogen, midostaurin, quizartinib, vosaroxin that are used for the treatment of acute myeloid leukemia. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.